Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.52 |
| ▸ | NOS1 | P29475 | 7/20 | 0.52 |
| ▸ | NOS3 | P29474 | 4/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15834091 | 0.90 | NOS2 (0.56) | NOS2NOS1NOS3EPHX2KDM5A | |
| SCHEMBL19633406 | 0.88 | MAP3K12 (0.41) | NOS2NOS1NOS3USP7KDM5A | |
| SCHEMBL21566710 | 0.88 | NOS2 (0.54) | NOS2NOS1NOS3EPHX2KDM5A | |
| SCHEMBL17303798 | 0.87 | NOS2 (0.68) | NOS2NOS1NOS3PTPN1EPHX2 | |
| SCHEMBL17573027 | 0.86 | NOS2 (0.53) | NOS2NOS1NOS3KDM5APRMT5 | |
| SCHEMBL17300787 | 0.84 | NOS2 (0.50) | NOS2NOS1NOS3PTPN1EPHX2 | |
| SCHEMBL19356328 | 0.84 | NOS2 (0.60) | NOS2NOS1NOS3KDM5APRMT5 | |
| SCHEMBL19171566 | 0.84 | NOS2 (0.51) | NOS2NOS1NOS3KDM5A | |
| SCHEMBL19287734 | 0.81 | KDM5A (0.51) | NOS2NOS1NOS3KDM5APRMT5 | |
| SCHEMBL19633748 | 0.81 | NOS2 (0.47) | NOS2NOS1NOS3PTPN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | NOS2 773/4885NOS1 580/4885NOS3 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.